MAbSilico

MAbSilico is an AI-powered platform for therapeutic antibody discovery, accelerating the design of high-affinity and epitope-specific humanized antibodies. It delivers lead candidates in just 21 days, optimizing for efficacy and manufacturability.

Claim this tool

1View

At a glance

Pricing

Likely Not Free

Free tier

API

Skill level

Technical

About

What is MAbSilico?

MAbSilico offers an AI-based solution for the rapid and efficient discovery of therapeutic antibody candidates. The platform leverages AI-driven docking and affinity prediction to design antibodies that bind to selected epitopes with high affinity and efficacy. It also evaluates inter-molecular and inter-species reactivity to minimize side effects and anticipate pre-clinical development needs. A key feature is the assessment of antibody sequence liabilities, such as post-translational modifications and aggregation motifs, to optimize stability and limit immunogenicity. MAbSilico aims to deliver fully characterized, high-affinity, and epitope-specific humanized antibodies within 21 days, significantly shortening the discovery pipeline and reducing development risks for biotech and pharma companies.

Best used for

Ideal for biotech and pharma companies who need to rapidly design therapeutic antibody candidates, evaluate their efficacy and safety, and optimize their developability. Especially valuable for accelerating drug discovery pipelines and reducing the time and cost associated with traditional antibody development.

Common actions

design antibodies

predict antibody affinity

optimize antibody manufacturability

accelerate drug discovery

Capabilities

Key features

AI-based antibody design
Affinity prediction
Epitope-specific design
Cross-reactivity evaluation
Manufacturability optimization
Humanized antibody delivery

Target Audience

startup founderdata scientistproduct manager

Integrations

Not yet documented

Pricing & Plans

Likely Not Free

Not publicly disclosed. Check mabsilico.com for current pricing.

FAQs

How quickly can MAbSilico deliver antibody candidates?

MAbSilico is designed to deliver fully characterized, high-affinity, and epitope-specific humanized antibody candidates within 21 days. This rapid turnaround aims to significantly accelerate the therapeutic antibody discovery process for its clients.

What aspects of antibody design does MAbSilico's AI optimize?

MAbSilico's AI optimizes several critical aspects including binding to selected epitopes with high affinity, evaluating cross-reactivity to limit side effects, and assessing manufacturability by identifying and mitigating sequence liabilities like PTMs and aggregation motifs.

Does MAbSilico help with pre-clinical development considerations?

Yes, MAbSilico evaluates inter-species reactivity during the design process. This helps anticipate binding for pre-clinical development, ensuring that the designed antibodies are more likely to perform as expected in subsequent testing phases.

Trending

Subcategories trending in Wellness & Lifestyle

Clinical & Healthcare Pro Health & Fitness Gaming & Entertainment Mental Wellness Self-Improvement Medical & Symptom Checking

Trending

Explore

Browse AI tools by category

Content & Design Productivity & Business Coding & Development AI Agents & Automation Research & Education Wellness & Lifestyle Career Development Marketing & Growth Data & Analytics Customer Support & CX Finance E-commerce